Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Security

Genmab A/S ADS · GMAB

GMABNASDAQotherCurrentCIK 1434265Updated Nov 19, 2026

Company: GENMAB A/S →

GMAB price & chart

Provider market data

Loading TradingView…

NASDAQ:GMAB on TradingView ↗

TradingView · Data may be delayed

About the company

Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody - drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.

6-K · 2026-11-10 · 0001434265-26-000148

Company description from the cited filing.

Financials

FY 2025 · USD
Revenue3,720,000,000USD · FY 2025
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

Net income— · FY 2025
Assets—USD · FY 2025
Cash— · FY 2025
Operating income1,065,000,000USD · FY 2025
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

Diluted EPS15.37USD per share · FY 2025
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

Some figures are unavailable for this reporting year.

Balance-sheet figures are unavailable pending verification.

cash flow · annual statements
Line itemQ2 2025Q2 2024Q2 2023Q2 2022Q2 2021Q2 2020Q2 2019Q2 2018FY 2025FY 2024FY 2023FY 2022
Cash flows from operating activities:
Profit or LossUSD336,000,000
Source

6-K · 2025-08-07 · 0001434265-25-000063

2025-04-01 to 2025-06-30

203,000,000
Source

6-K · 2025-08-07 · 0001434265-25-000063

2024-04-01 to 2024-06-30

1,335,000,000
Source

6-K · 2024-08-08 · 0001558370-24-011511

2023-04-01 to 2023-06-30

1,891,000,000
Source

6-K · 2023-08-03 · 0001558370-23-013113

2022-04-01 to 2022-06-30

306,000,000
Source

6-K · 2022-08-10 · 0001558370-22-012999

2021-04-01 to 2021-06-30

3,378,000,000
Source

6-K · 2021-08-11 · 0001558370-21-011244

2020-04-01 to 2020-06-30

85,000,000
Source

6-K · 2020-08-12 · 0001558370-20-010409

2019-04-01 to 2019-06-30

260,527,000
Source

6-K · 2019-08-14 · 0001558370-19-008146

2018-04-01 to 2018-06-30

963,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

7,844,000,000
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

4,352,000,000
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

5,522,000,000
Source

6-K · 2023-02-22 · 0001558370-23-001700

2022-01-01 to 2022-12-31

Additional Financial Items
AdjustmentsForDeferredTaxOfPriorPeriodsUSD————————-63,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

99,000,000
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

-59,000,000
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

107,000,000
Source

6-K · 2023-02-22 · 0001558370-23-001700

2022-01-01 to 2022-12-31

AdjustmentsForFinanceCostsUSD————————269,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

1,977,000,000
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

——
AdjustmentsForFinanceIncomeUSD————————408,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

4,438,000,000
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

——
AdjustmentsForIncomeTaxExpenseUSD————————-460,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

-343,000,000
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

-1,067,000,000
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

-1,583,000,000
Source

6-K · 2023-02-22 · 0001558370-23-001700

2022-01-01 to 2022-12-31

AdjustmentsForSharebasedPaymentsUSD————————128,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

721,000,000
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

586,000,000
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

439,000,000
Source

6-K · 2023-02-22 · 0001558370-23-001700

2022-01-01 to 2022-12-31

GoodwillUSD355,000,000
Source

6-K · 2025-08-07 · 0001434265-25-000063

As of 2025-06-30

2,518,000,000
Source

6-K · 2024-08-08 · 0001558370-24-011511

As of 2024-06-30

——————355,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

As of 2025-12-31

2,535,000,000
Source

6-K · 2025-02-12 · 0001558370-25-000831

As of 2024-12-31

——
IncreaseDecreaseInWorkingCapitalDKK——————————-1,362,000,000
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

1,930,000,000
Source

6-K · 2023-02-22 · 0001558370-23-001700

2022-01-01 to 2022-12-31

InterestPaidClassifiedAsOperatingActivitiesUSD————————5,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

—1,000,000
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

1,000,000
Source

6-K · 2023-02-22 · 0001558370-23-001700

2022-01-01 to 2022-12-31

InterestReceivedClassifiedAsOperatingActivitiesUSD————————135,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

935,000,000
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

908,000,000
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

283,000,000
Source

6-K · 2023-02-22 · 0001558370-23-001700

2022-01-01 to 2022-12-31

PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD————————13,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

60,000,000
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

91,000,000
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

73,000,000
Source

6-K · 2023-02-22 · 0001558370-23-001700

2022-01-01 to 2022-12-31

ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD————————5,500,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

———
ProceedsFromSalesOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethodUSD————————2,622,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

11,279,000,000
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

10,001,000,000
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

7,254,000,000
Source

6-K · 2023-02-22 · 0001558370-23-001700

2022-01-01 to 2022-12-31

PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD————————18,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

117,000,000
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

10,000,000
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

—
RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesUSD————————273,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

———
GeneralAndAdministrativeExpense—————
Source

6-K · 2021-08-11 · 0001558370-21-011244

2021-04-01 to 2021-06-30

—
Source

6-K · 2021-08-11 · 0001558370-21-011244

2020-04-01 to 2020-06-30

—
Source

6-K · 2020-08-12 · 0001558370-20-010409

2019-04-01 to 2019-06-30

—
Source

6-K · 2019-08-14 · 0001558370-19-008146

2018-04-01 to 2018-06-30

————

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements
Line itemQ2 2025Q2 2024Q2 2023Q2 2022Q2 2021Q2 2020Q2 2019Q2 2018FY 2025FY 2024FY 2023FY 2022
Cost of Goods and Services Sold—
Source

6-K · 2025-08-07 · 0001434265-25-000063

2025-04-01 to 2025-06-30

—
Source

6-K · 2025-08-07 · 0001434265-25-000063

2024-04-01 to 2024-06-30

—
Source

6-K · 2024-08-08 · 0001558370-24-011511

2023-04-01 to 2023-06-30

——————
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

—
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

—
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

—
Gross Profit (Calculated) · Derived————————————
Selling, General and Administrative ExpenseUSD144,000,000
Source

6-K · 2025-08-07 · 0001434265-25-000063

2025-04-01 to 2025-06-30

129,000,000
Source

6-K · 2025-08-07 · 0001434265-25-000063

2024-04-01 to 2024-06-30

827,000,000
Source

6-K · 2024-08-08 · 0001558370-24-011511

2023-04-01 to 2023-06-30

633,000,000
Source

6-K · 2023-08-03 · 0001558370-23-013113

2022-04-01 to 2022-06-30

264,000,000
Source

6-K · 2022-08-10 · 0001558370-22-012999

2021-04-01 to 2021-06-30

———626,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

3,790,000,000
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

3,297,000,000
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

2,676,000,000
Source

6-K · 2023-02-22 · 0001558370-23-001700

2022-01-01 to 2022-12-31

Total RevenueUSD925,000,000
Source

6-K · 2025-08-07 · 0001434265-25-000063

2025-04-01 to 2025-06-30

779,000,000
Source

6-K · 2025-08-07 · 0001434265-25-000063

2024-04-01 to 2024-06-30

4,169,000,000
Source

6-K · 2024-08-08 · 0001558370-24-011511

2023-04-01 to 2023-06-30

3,162,000,000
Source

6-K · 2023-08-03 · 0001558370-23-013113

2022-04-01 to 2022-06-30

1,972,000,000
Source

6-K · 2022-08-10 · 0001558370-22-012999

2021-04-01 to 2021-06-30

5,451,000,000
Source

6-K · 2021-08-11 · 0001558370-21-011244

2020-04-01 to 2020-06-30

774,000,000
Source

6-K · 2020-08-12 · 0001558370-20-010409

2019-04-01 to 2019-06-30

509,675,000
Source

6-K · 2019-08-14 · 0001558370-19-008146

2018-04-01 to 2018-06-30

3,720,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

21,526,000,000
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

16,474,000,000
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

14,595,000,000
Source

6-K · 2023-02-22 · 0001558370-23-001700

2022-01-01 to 2022-12-31

Additional Financial Items
ApplicableTaxRatenumber————————0.22
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

0.22
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

0.22
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

0.22
Source

6-K · 2023-02-22 · 0001558370-23-001700

2022-01-01 to 2022-12-31

AverageEffectiveTaxRatenumber————————0.2
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

0.14
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

0.23
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

0.22
Source

6-K · 2023-02-22 · 0001558370-23-001700

2022-01-01 to 2022-12-31

BasicEarningsLossPerShareUSD per share5.44
Source

6-K · 2025-08-07 · 0001434265-25-000063

2025-04-01 to 2025-06-30

3.15
Source

6-K · 2025-08-07 · 0001434265-25-000063

2024-04-01 to 2024-06-30

20.46
Source

6-K · 2024-08-08 · 0001558370-24-011511

2023-04-01 to 2023-06-30

28.87
Source

6-K · 2023-08-03 · 0001558370-23-013113

2022-04-01 to 2022-06-30

4.68
Source

6-K · 2022-08-10 · 0001558370-22-012999

2021-04-01 to 2021-06-30

51.88
Source

6-K · 2021-08-11 · 0001558370-21-011244

2020-04-01 to 2020-06-30

1.38
Source

6-K · 2020-08-12 · 0001558370-20-010409

2019-04-01 to 2019-06-30

4.26
Source

6-K · 2019-08-14 · 0001558370-19-008146

2018-04-01 to 2018-06-30

15.5
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

122.21
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

66.64
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

84.45
Source

6-K · 2023-02-22 · 0001558370-23-001700

2022-01-01 to 2022-12-31

CurrentTaxExpenseIncomeUSD————————256,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

1,799,000,000
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

1,301,000,000
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

1,498,000,000
Source

6-K · 2023-02-22 · 0001558370-23-001700

2022-01-01 to 2022-12-31

DeferredTaxExpenseIncomeRecognisedInProfitOrLossUSD————————10,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

———
DepreciationRightofuseAssetsUSD4,000,000
Source

6-K · 2025-08-07 · 0001434265-25-000063

2025-04-01 to 2025-06-30

4,000,000
Source

6-K · 2025-08-07 · 0001434265-25-000063

2024-04-01 to 2024-06-30

23,000,000
Source

6-K · 2024-08-08 · 0001558370-24-011511

2023-04-01 to 2023-06-30

16,000,000
Source

6-K · 2023-08-03 · 0001558370-23-013113

2022-04-01 to 2022-06-30

————17,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

102,000,000
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

87,000,000
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

74,000,000
Source

6-K · 2023-02-22 · 0001558370-23-001700

2022-01-01 to 2022-12-31

DilutedEarningsLossPerShareUSD per share5.42
Source

6-K · 2025-08-07 · 0001434265-25-000063

2025-04-01 to 2025-06-30

3.13
Source

6-K · 2025-08-07 · 0001434265-25-000063

2024-04-01 to 2024-06-30

20.28
Source

6-K · 2024-08-08 · 0001558370-24-011511

2023-04-01 to 2023-06-30

28.66
Source

6-K · 2023-08-03 · 0001558370-23-013113

2022-04-01 to 2022-06-30

4.64
Source

6-K · 2022-08-10 · 0001558370-22-012999

2021-04-01 to 2021-06-30

51.35
Source

6-K · 2021-08-11 · 0001558370-21-011244

2020-04-01 to 2020-06-30

1.35
Source

6-K · 2020-08-12 · 0001558370-20-010409

2019-04-01 to 2019-06-30

4.21
Source

6-K · 2019-08-14 · 0001558370-19-008146

2018-04-01 to 2018-06-30

15.37
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

121.36
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

66.02
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

83.65
Source

6-K · 2023-02-22 · 0001558370-23-001700

2022-01-01 to 2022-12-31

EmployeeBenefitsExpenseUSD————————763,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

4,344,000,000
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

3,548,000,000
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

2,583,000,000
Source

6-K · 2023-02-22 · 0001558370-23-001700

2022-01-01 to 2022-12-31

ExpenseFromSharebasedPaymentTransactionsWithEmployeesUSD————————128,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

721,000,000
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

586,000,000
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

439,000,000
Source

6-K · 2023-02-22 · 0001558370-23-001700

2022-01-01 to 2022-12-31

FinanceCostsUSD91,000,000
Source

6-K · 2025-08-07 · 0001434265-25-000063

2025-04-01 to 2025-06-30

46,000,000
Source

6-K · 2025-08-07 · 0001434265-25-000063

2024-04-01 to 2024-06-30

120,000,000
Source

6-K · 2024-08-08 · 0001558370-24-011511

2023-04-01 to 2023-06-30

200,000,000
Source

6-K · 2023-08-03 · 0001558370-23-013113

2022-04-01 to 2022-06-30

430,000,000
Source

6-K · 2022-08-10 · 0001558370-22-012999

2021-04-01 to 2021-06-30

211,000,000
Source

6-K · 2021-08-11 · 0001558370-21-011244

2020-04-01 to 2020-06-30

60,000,000
Source

6-K · 2020-08-12 · 0001558370-20-010409

2019-04-01 to 2019-06-30

—269,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

1,977,000,000
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

942,000,000
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

680,000,000
Source

6-K · 2023-02-22 · 0001558370-23-001700

2022-01-01 to 2022-12-31

FinanceIncomeUSD154,000,000
Source

6-K · 2025-08-07 · 0001434265-25-000063

2025-04-01 to 2025-06-30

117,000,000
Source

6-K · 2025-08-07 · 0001434265-25-000063

2024-04-01 to 2024-06-30

346,000,000
Source

6-K · 2024-08-08 · 0001558370-24-011511

2023-04-01 to 2023-06-30

1,442,000,000
Source

6-K · 2023-08-03 · 0001558370-23-013113

2022-04-01 to 2022-06-30

65,000,000
Source

6-K · 2022-08-10 · 0001558370-22-012999

2021-04-01 to 2021-06-30

42,000,000
Source

6-K · 2021-08-11 · 0001558370-21-011244

2020-04-01 to 2020-06-30

34,000,000
Source

6-K · 2020-08-12 · 0001558370-20-010409

2019-04-01 to 2019-06-30

—408,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

4,438,000,000
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

1,258,000,000
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

1,358,000,000
Source

6-K · 2023-02-22 · 0001558370-23-001700

2022-01-01 to 2022-12-31

ImpairmentLossRecognisedInProfitOrLossGoodwillUSD————————0
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

0
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

——
IncomeTaxExpenseContinuingOperationsUSD87,000,000
Source

6-K · 2025-08-07 · 0001434265-25-000063

2025-04-01 to 2025-06-30

104,000,000
Source

6-K · 2025-08-07 · 0001434265-25-000063

2024-04-01 to 2024-06-30

359,000,000
Source

6-K · 2024-08-08 · 0001558370-24-011511

2023-04-01 to 2023-06-30

598,000,000
Source

6-K · 2023-08-03 · 0001558370-23-013113

2022-04-01 to 2022-06-30

116,000,000
Source

6-K · 2022-08-10 · 0001558370-22-012999

2021-04-01 to 2021-06-30

950,000,000
Source

6-K · 2021-08-11 · 0001558370-21-011244

2020-04-01 to 2020-06-30

26,000,000
Source

6-K · 2020-08-12 · 0001558370-20-010409

2019-04-01 to 2019-06-30

74,788,000
Source

6-K · 2019-08-14 · 0001558370-19-008146

2018-04-01 to 2018-06-30

241,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

1,320,000,000
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

1,285,000,000
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

1,513,000,000
Source

6-K · 2023-02-22 · 0001558370-23-001700

2022-01-01 to 2022-12-31

NetForeignExchangeLossDKK77,000,000
Source

6-K · 2025-08-07 · 0001434265-25-000063

2025-04-01 to 2025-06-30

17,000,000
Source

6-K · 2025-08-07 · 0001434265-25-000063

2024-04-01 to 2024-06-30

10,000,000
Source

6-K · 2024-08-08 · 0001558370-24-011511

2023-04-01 to 2023-06-30

——————1,594,000,000
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

889,000,000
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

—
PostemploymentBenefitExpenseDefinedBenefitPlansUSD————————34,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

205,000,000
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

170,000,000
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

112,000,000
Source

6-K · 2023-02-22 · 0001558370-23-001700

2022-01-01 to 2022-12-31

ProfitLossBeforeTaxUSD423,000,000
Source

6-K · 2025-08-07 · 0001434265-25-000063

2025-04-01 to 2025-06-30

307,000,000
Source

6-K · 2025-08-07 · 0001434265-25-000063

2024-04-01 to 2024-06-30

1,694,000,000
Source

6-K · 2024-08-08 · 0001558370-24-011511

2023-04-01 to 2023-06-30

2,489,000,000
Source

6-K · 2023-08-03 · 0001558370-23-013113

2022-04-01 to 2022-06-30

422,000,000
Source

6-K · 2022-08-10 · 0001558370-22-012999

2021-04-01 to 2021-06-30

4,328,000,000
Source

6-K · 2021-08-11 · 0001558370-21-011244

2020-04-01 to 2020-06-30

111,000,000
Source

6-K · 2020-08-12 · 0001558370-20-010409

2019-04-01 to 2019-06-30

335,315,000
Source

6-K · 2019-08-14 · 0001558370-19-008146

2018-04-01 to 2018-06-30

1,204,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

9,164,000,000
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

5,637,000,000
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

7,035,000,000
Source

6-K · 2023-02-22 · 0001558370-23-001700

2022-01-01 to 2022-12-31

ProfitLossFromOperatingActivitiesUSD360,000,000
Source

6-K · 2025-08-07 · 0001434265-25-000063

2025-04-01 to 2025-06-30

236,000,000
Source

6-K · 2025-08-07 · 0001434265-25-000063

2024-04-01 to 2024-06-30

1,468,000,000
Source

6-K · 2024-08-08 · 0001558370-24-011511

2023-04-01 to 2023-06-30

1,247,000,000
Source

6-K · 2023-08-03 · 0001558370-23-013113

2022-04-01 to 2022-06-30

787,000,000
Source

6-K · 2022-08-10 · 0001558370-22-012999

2021-04-01 to 2021-06-30

4,497,000,000
Source

6-K · 2021-08-11 · 0001558370-21-011244

2020-04-01 to 2020-06-30

137,000,000
Source

6-K · 2020-08-12 · 0001558370-20-010409

2019-04-01 to 2019-06-30

135,044,000
Source

6-K · 2019-08-14 · 0001558370-19-008146

2018-04-01 to 2018-06-30

1,065,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

6,703,000,000
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

5,321,000,000
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

6,357,000,000
Source

6-K · 2023-02-22 · 0001558370-23-001700

2022-01-01 to 2022-12-31

ResearchAndDevelopmentExpenseUSD364,000,000
Source

6-K · 2025-08-07 · 0001434265-25-000063

2025-04-01 to 2025-06-30

361,000,000
Source

6-K · 2025-08-07 · 0001434265-25-000063

2024-04-01 to 2024-06-30

1,853,000,000
Source

6-K · 2024-08-08 · 0001558370-24-011511

2023-04-01 to 2023-06-30

1,282,000,000
Source

6-K · 2023-08-03 · 0001558370-23-013113

2022-04-01 to 2022-06-30

921,000,000
Source

6-K · 2022-08-10 · 0001558370-22-012999

2021-04-01 to 2021-06-30

775,000,000
Source

6-K · 2021-08-11 · 0001558370-21-011244

2020-04-01 to 2020-06-30

564,000,000
Source

6-K · 2020-08-12 · 0001558370-20-010409

2019-04-01 to 2019-06-30

318,889,000
Source

6-K · 2019-08-14 · 0001558370-19-008146

2018-04-01 to 2018-06-30

1,606,000,000
Source

20-F · 2026-02-17 · 0001434265-26-000014

2025-01-01 to 2025-12-31

9,748,000,000
Source

6-K · 2025-02-12 · 0001558370-25-000831

2024-01-01 to 2024-12-31

7,630,000,000
Source

6-K · 2024-02-14 · 0001558370-24-001134

2023-01-01 to 2023-12-31

5,562,000,000
Source

6-K · 2023-02-22 · 0001558370-23-001700

2022-01-01 to 2022-12-31

GeneralAndAdministrativeExpense—————
Source

6-K · 2021-08-11 · 0001558370-21-011244

2021-04-01 to 2021-06-30

—
Source

6-K · 2021-08-11 · 0001558370-21-011244

2020-04-01 to 2020-06-30

—
Source

6-K · 2020-08-12 · 0001558370-20-010409

2019-04-01 to 2019-06-30

—
Source

6-K · 2019-08-14 · 0001558370-19-008146

2018-04-01 to 2018-06-30

————
InterestExpenseOnLeaseLiabilities———
Source

6-K · 2023-08-03 · 0001558370-23-013113

2023-04-01 to 2023-06-30

—
Source

6-K · 2023-08-03 · 0001558370-23-013113

2022-04-01 to 2022-06-30

————————

Lines labelled “Derived” are calculated from reported figures.

Filing attachments

gmab_20261110xex99d1.htm · 6-K · 2026-11-10

Exhibit 99.1 Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; November 10, 2026 - Genmab A/S (Nasdaq: GMAB) will increase its share capital by 164,828 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 2,961 shares at DKK 1,3…

6-K · 2026-11-10 · 0001434265-26-000148

Read attachment ↗
gmab_20261028xex99d1.htm · 6-K · 2026-10-28

Exhibit 99.1 Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer Company Announcement COPENHAGEN, Denmark; October 28, 2026 • Phase 3 LiGeR-HN1 trial of Petosemtamab in combination with pembrolizumab versus pembrolizumab alone met both primary endpoints, reducing the risk of death by 50% in patients with PD-L1…

6-K · 2026-10-28 · 0001434265-26-000140

Read attachment ↗
gmab_20261023xex99d1.htm · 6-K · 2026-10-23

Exhibit 99.1 Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer Company Announcement COPENHAGEN, Denmark; October 23, 2026 • Phase 3 RAINFOL™-02 trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS) with rinatabart sesutecan (Rina-S®) compared to investigator’s choice chemothera…

6-K · 2026-10-23 · 0001434265-26-000138

Read attachment ↗
gmab_20261013xex99d1.htm · 6-K · 2026-10-13

Exhibit 99.1 Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026 Company Announcement • Net sales of DARZALEX® in the third quarter of 2026 totaled USD 4,239 million • Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; October 13, 2026 - Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) prod…

6-K · 2026-10-13 · 0001434265-26-000136

Read attachment ↗
gmab_20261007xex99d1.htm · 6-K · 2026-10-07

Exhibit 99.1 Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members Company Announcement COPENHAGEN, Denmark; October 7, 2026 - Genmab A/S (Nasdaq: GMAB) Today, Genmab A/S held an Extraordinary General Meeting. At the Extraordinary General Meeting the proposal from the Board of Directors on remuneration of the Board of Directors for 2026, including share-based remuneration in the form of restricted stock units, was ap…

6-K · 2026-10-07 · 0001434265-26-000134

Read attachment ↗
gmab_20261015xex99d1.htm · 6-K · 2026-10-05

Exhibit 99.1 Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Company Announcement COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; October 5, 2026 • EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free surv…

6-K · 2026-10-05 · 0001434265-26-000132

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.